The Native Antigen Company announced the introduction of its custom contract service to rapidly develop antigen panels for influenza A and B viruses. This new service will provide scientists access to proteins from emerging seasonal and pandemic influenza strains, to support ongoing research and development of diagnostics and vaccines. The Native Antigen Company provides custom contract services to develop panels of the influenza antigens from a wide range of virus strains and subtypes using its proprietary HEK293 mammalian expression system (VirtuE), which is able to introduce proper protein folding and full glycosylation to closely mimic naturally occurring proteins.